Physician profile
Brianne Ayers
NPI 1407225212
$3,610.33
in general payments reported to CMS, 2019-2025
25 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $471 · 2022: $543 · 2023: $528 · 2024: $911 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537 · Education: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.40 |
| Education | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $794.68 | 2021-2025 | Tezspire, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $500.15 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Blueprint Medicines Corporation | $264.48 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $223.90 | 2021-2025 | Eohilia, Hyqvia, Cuvitru |
| Csl Behring | $214.03 | 2021-2025 | Hizentra |
| Grifols USA, LLC | $200.60 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $194.39 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $178.52 | 2021-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $154.87 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $149.81 | 2021-2025 | |
| Kaleo, INC. | $129.63 | 2021-2022 | |
| Incyte Corporation | $97.04 | 2024-2025 | Opzelura |
| Amgen INC. | $86.98 | 2025 | Tezspire |
| Ionis Pharmaceuticals, INC. | $72.73 | 2025 | Dawnzera |
| Pfizer INC. | $71.98 | 2021-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $50.51 | 2025 | Vtama |
| Genentech USA, INC. | $47.50 | 2024-2025 | Xolair |
| Mylan Specialty L.P. | $37.39 | 2022-2024 | Yupelri |
| Tersera Therapeutics LLC | $37.39 | 2024 | Quzyttir |
| Leo Pharma INC. | $23.96 | 2024 | Adbry |
| Pharming Healthcare, INC. | $23.49 | 2024 | Ruconest |
| Verona Pharma, INC. | $21.00 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $13.97 | 2021 | |
| Uswm, LLC | $13.00 | 2021 | |
| Cycle Pharmaceuticals INC | $8.33 | 2024 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianne Ayers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.